drugset / Trial / NCT02618356
Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The primary endpoint is to evaluate the Median disease progression free survival (mPFS).
Timeline
- Start
- 2015-12-25
- Primary completion
- 2017-11
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Raltitrexed | Small molecule | 3 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 80 mg | Oral |
| Subject | S-1 | Small molecule | 100 mg | Oral |
| Subject | S-1 | Small molecule | 120 mg | Oral |